Moderna lowers top end of revenue guidance as vaccine group targets cost cuts

Moderna (NASDAQ: MRNA) has lowered its full-year revenue forecast to $1.5 billion-$2.2 billion from a prior estimate of $1.5 billion-$2.5 billion, citing a delay in UK vaccine deliveries to the next fiscal year, which led to a premarket share decline. This revision follows the company's recent 10% headcount reduction and broader cost-cutting efforts aimed at mitigating flagging COVID-19 vaccine sales, despite its second-quarter operating expenses decreasing by 35% and both revenue and loss per share outperforming analyst expectations.

Analysis

Moderna has revised its full-year revenue forecast downward to a range of $1.5 billion to $2.2 billion, from a prior top-end of $2.5 billion, attributing the change to a delay in UK vaccine deliveries. This new guidance places the midpoint below the Bloomberg consensus estimate of $2.07 billion, signaling persistent headwinds from flagging sales of its primary COVID-19 product. This outlook revision follows a recent announcement of a 10% global staff reduction, a key part of a broader strategy to manage its cost base. These cost-cutting efforts are already showing results, with second-quarter operating expenses declining 35% year-over-year to $1.05 billion. Despite a significant 41% drop in Q2 revenue to $142 million, the company surpassed analyst expectations on both the top line and its loss per share of $2.13, indicating some operational resilience amidst a difficult transitional period.

Key Decisions for Investors

• Investors should weigh the negative impact of the lowered full-year revenue guidance, which signals ongoing demand challenges and a potential miss against current market expectations.
• The successful 35% reduction in quarterly operating expenses and the announced 10% staff cut are critical metrics to monitor, as management's ability to right-size the cost structure is crucial for achieving profitability.
• Given the Q2 revenue and EPS beat against a backdrop of declining sales, investors should scrutinize future earnings reports for continued evidence of operational discipline and any stabilization in product demand.